GNPX vs. PCSA, ZVSA, LIPO, THAR, KTRA, ARTL, ENSC, BPTS, KZIA, and VRPX
Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Processa Pharmaceuticals (PCSA), ZyVersa Therapeutics (ZVSA), Lipella Pharmaceuticals (LIPO), Tharimmune (THAR), Kintara Therapeutics (KTRA), Artelo Biosciences (ARTL), Ensysce Biosciences (ENSC), Biophytis (BPTS), Kazia Therapeutics (KZIA), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical preparations" industry.
Processa Pharmaceuticals (NASDAQ:PCSA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
Processa Pharmaceuticals is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.
Processa Pharmaceuticals has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.61, meaning that its stock price is 161% less volatile than the S&P 500.
91.9% of Processa Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 22.2% of Processa Pharmaceuticals shares are owned by company insiders. Comparatively, 11.5% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Genprex's average media sentiment score of 0.00 equaled Processa Pharmaceuticals'average media sentiment score.
Genprex's return on equity of -141.42% beat Processa Pharmaceuticals' return on equity.
Genprex has a consensus target price of $10.00, suggesting a potential upside of 362.96%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Genprex is more favorable than Processa Pharmaceuticals.
Genprex received 190 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. Likewise, 65.13% of users gave Genprex an outperform vote while only 44.44% of users gave Processa Pharmaceuticals an outperform vote.
Summary
Processa Pharmaceuticals beats Genprex on 7 of the 12 factors compared between the two stocks.
Get Genprex News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
